Cellular mechanism of decreased bone in Brtl mouse model of OI: imbalance of decreased osteoblast function and increased osteoclasts and their precursors.
about
Increased susceptibility to microdamage in Brtl/+ mouse model for osteogenesis imperfecta.Effect of anti-sclerostin therapy and osteogenesis imperfecta on tissue-level properties in growing and adult mice while controlling for tissue age.Induced ablation of Bmp1 and Tll1 produces osteogenesis imperfecta in mice.Immature osteoblast lineage cells increase osteoclastogenesis in osteogenesis imperfecta murine.Potential implications of cell therapy for osteogenesis imperfecta.First mouse model for combined osteogenesis imperfecta and Ehlers-Danlos syndrome.Myostatin deficiency partially rescues the bone phenotype of osteogenesis imperfecta model mice.Molecular, phenotypic aspects and therapeutic horizons of rare genetic bone disorders.Chaperoning osteogenesis: new protein-folding disease paradigms.Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatmentVariable bone fragility associated with an Amish COL1A2 variant and a knock-in mouse model.Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength.Altered cytoskeletal organization characterized lethal but not surviving Brtl+/- mice: insight on phenotypic variability in osteogenesis imperfectaImpaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy.Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta.Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formationIn utero transplantation of adult bone marrow decreases perinatal lethality and rescues the bone phenotype in the knockin murine model for classical, dominant osteogenesis imperfecta.RANKL inhibition for the management of patients with benign metabolic bone disorders.Fracture healing with alendronate treatment in the Brtl/+ mouse model of osteogenesis imperfectaNew perspectives on osteogenesis imperfectaSex-Linked Skeletal Phenotype of Lysyl Oxidase Like-1 Mutant Mice.Mineral and matrix changes in Brtl/+ teeth provide insights into mineralization mechanisms.Single dose of bisphosphonate preserves gains in bone mass following cessation of sclerostin antibody in Brtl/+ osteogenesis imperfecta model.Splenomegaly, myeloid lineage expansion and increased osteoclastogenesis in osteogenesis imperfecta murine.Osteogenesis imperfecta and therapeutics.Genetic causes and mechanisms of Osteogenesis Imperfecta.Impaired bone remodeling in children with osteogenesis imperfecta treated and untreated with bisphosphonates: the role of DKK1, RANKL, and TNF-α.
P2860
Q30463549-07DEA573-C5C6-4DF9-8915-3BB441D35CC3Q30713102-7308D540-EF6E-472B-A357-16F5DA291437Q33649249-7BD65A62-C30D-4624-A029-C5FB3E7A91D6Q33816415-676F7719-F855-49EA-918F-8486527C963CQ33863266-2D429FEA-6988-487E-A2FD-DC40910681EFQ34398977-ABE8C3AC-C8CE-450A-8EAC-540B2C8B40D3Q34485335-CDAFBC0F-6BD8-408F-9511-A942AEF57078Q34502398-5AF83539-EB5D-4A8F-97E8-9A28241AFF53Q34672644-C7CD320A-CF10-43E6-AD77-E71CF6C1A598Q34759279-EC1B2DA2-7313-4B28-9112-B71BA08D0AE6Q35156234-505A20A2-D272-416B-9679-D5C1F19B1861Q35555545-E4C3DA53-AEEA-469C-99C0-5C0732527BDDQ36167524-12673621-ED30-4010-9FCD-BE83EE2D3053Q36282399-BB9677B4-6A12-4C5F-90F1-DC492562A0B5Q36472781-99EC97EF-02B8-4705-BA2F-B992DDD9FD85Q37166804-74668B49-F130-4BA6-9827-8E45B322EC72Q37271063-D5DE9709-A5B1-420E-AC58-6DEAF0FF73FCQ37532561-3EF8EEF9-BD78-4105-88AF-9B01484B468CQ37722288-782AF4A2-0DBA-4CFA-8E29-181BE4A5E2B5Q37889113-A19864FF-5C1C-4481-84E6-9133DB2194C8Q40354992-7D1C60E7-3C35-4E27-8E94-7096277D813FQ41876168-8C2C8492-7916-4110-95AA-0F3E41858F13Q47099469-3DF2D69B-A97A-4D37-8309-3DF48257BAB7Q51816827-B78E1CE5-85F7-43F9-8840-00C30906FED7Q52655586-5EF4A12B-F11C-4C63-978C-CDD3F98A26E0Q52679260-16566CE8-3293-4C38-A55C-2C69714D4C30Q53180647-90E3B327-E8C7-4DB7-BC1F-593EDCD5B1BD
P2860
Cellular mechanism of decreased bone in Brtl mouse model of OI: imbalance of decreased osteoblast function and increased osteoclasts and their precursors.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Cellular mechanism of decrease ...... eoclasts and their precursors.
@en
type
label
Cellular mechanism of decrease ...... eoclasts and their precursors.
@en
prefLabel
Cellular mechanism of decrease ...... eoclasts and their precursors.
@en
P2093
P2860
P356
P1476
Cellular mechanism of decrease ...... eoclasts and their precursors.
@en
P2093
Antonella Forlino
Clemens Bergwitz
Felicia Ledgard
Joan C Marini
Leah Goldberg
Patricia Collin-Osdoby
Philip Osdoby
Thomas E Uveges
Wayne A Cabral
P2860
P304
P356
10.1359/JBMR.080804
P577
2008-12-01T00:00:00Z